Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 31, Number 9—September 2025

Research Letter

Linezolid and Meropenem for Nocardia otitidiscaviarum Actinomycetoma, India

Kabir SardanaComments to Author , Savitha Sharath, Soumya Sachdeva, Shukla Das, Gargi Rai, and Praveen Kumar Singh
Author affiliation: Atal Bihari Vajpayee Institute of Medical Sciences and Research Institute and Dr Ram Manohar Lohia Hospital, New Delhi, India (K. Sardana, S. Sharath, S. Sachdeva); University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi (S. Das, G. Rai, P.K. Singh)

Main Article

Figure 1

Anterior right knee of patient treated with linezolid and meropenem for Nocardia otitidiscaviarum actinomycetoma, India. A) Multiple nodules with overlying sinuses over right knee. B) Near-complete resolution with subsidence of sinuses and nodules leaving behind scarring after 2 months of treatment with a 21-day cycle of linezolid and meropenem combined with trimethoprim/sulfamethoxazole.

Figure 1. Anterior right knee of patient treated with linezolid and meropenem for Nocardia otitidiscaviarum actinomycetoma, India. A) Multiple nodules with overlying sinuses over right knee. B) Near-complete resolution with subsidence of sinuses and nodules leaving behind scarring after 2 months of treatment with a 21-day cycle of linezolid and meropenem combined with trimethoprim/sulfamethoxazole.

Main Article

Page created: July 01, 2025
Page updated: August 26, 2025
Page reviewed: August 26, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external